E.g., 12/03/2021
E.g., 12/03/2021
Title Category Credit Event date Price
Genetic Testing and Personalized Medicine in Prostate Cancer Podcast (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Genetic Testing in Prostate Cancer: Understanding Clinical Implications for Early Detection, Localized Disease, & Castration Resistant Prostate...
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 There has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer over the last several years. While the clinical impact of BRCA1/2 mutations has been well established in the setting of breast and ovarian cancer with critical implications for treatment (e.g.
Identification and Management of Comorbid Conditions in the Patient with Advanced Prostate Cancer Podcast (2021)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA has developed a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Incorporating Genomic Testing For Prostate Cancer into Your Practice Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 There are multiple genomic tests currently available for men with localized prostate cancer. The outcomes of these tests may lead to different treatment decisions (active surveillance, surgery, radiation, etc) or impact the frequency of monitoring. The availability and marketing of genomic testing has outpaced a reflective, evidence based medicine approach to using these tests.
Life Long Learning Prep Course Webcast: Module 1: Oncology, Urinary Diversion and Adrenal (2021) $1,055.00 Specifically designed for anyone unable to get away from the office to attend the Live Course, the Webcast option delivers the same great content. Purchase of the Webcast features simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials.
Live from AUA2021: Highlights in Advanced Prostate Cancer (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 Live from AUA2021: Highlights in Advanced Prostate Cancer is a panel discussion filmed LIVE at the 2021 AUA Annual Meeting!
Live Webinar 1: PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
03/24/2021 $0.00 Complimentary CME Webinar!Wednesday, March 24, 2021 | 7:00 - 8:00 p.m. ESTPARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors.
Live Webinar 2: PARP Inhibitors: Assessing the Clinical Trial Landscape (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
04/14/2021 $0.00 Complimentary CME Webinar!Wednesday, April 14, 2021 | 7:00 - 8:00 p.m. ESTPARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors.
Live Webinar 3: PARP Inhibitors: Best Practices in Advanced Prostate Cancer Care in the Community (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
04/27/2021 $0.00 Complimentary CME Webinar!Tuesday, April 27, 2021 | 7:00 - 8:00 p.m. ESTPARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors.
Management of Non Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 This course will review the most recent AUA practice guidelines for non-muscle-invasive bladder cancer and detail strategies to manage common clinical predicaments involved in the management of these tumors. Specifically we will review: the AUA guidelines; risk stratification and use of cystectomy; selection of the optimal intravesical agent at the right schedule; and treatment of toxicity from intravesical therapy. Practical solutions will be presented that can be readily integrated into the office setting.
Metastatic Hormone Sensitive Prostate Cancer: Expert Guidance for Urologists Webcast (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 In just the last decade, the FDA has approved several new therapies for the treatment of prostate cancer. It is critical for urologists to understand the sequencing of agents for the treatment of mHSPC because of the overlapping toxicities and the increasing role for treating mHSPC patients. For each new agent, urologists should be able to identify the active agents and their mechanism of action, analyze the breakthrough treatments in the management of advanced and mHSPC, and describe the indications and combinations for treatment with approved agents in the management of mHSPC.
Novel Imaging for High Risk Prostate Cancer Podcast (2021)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA has developed a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
PARP Inhibitors: Assessing the Clinical Trial Landscape Webcast (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion. 
PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape Webcast (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion. 
PARP Inhibitors: Best Practices in Advanced Prostate Cancer Care in the Community Webcast (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00

Pages